204 related articles for article (PubMed ID: 3332173)
1. Graft-versus-leukemia following bone marrow transplantation.
Butturini A; Bortin MM; Gale RP
Bone Marrow Transplant; 1987 Oct; 2(3):233-42. PubMed ID: 3332173
[TBL] [Abstract][Full Text] [Related]
2. Graft-vs-leukemia following bone marrow transplantation: a model of immunotherapy in man.
Butturini A; Bortin MM; Seeger RC; Gale RP
Prog Clin Biol Res; 1987; 244():371-90. PubMed ID: 3310000
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry.
Gale RP; Horowitz MM
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():94-7. PubMed ID: 2390646
[TBL] [Abstract][Full Text] [Related]
4. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
5. The graft versus leukemia effect: possible mechanisms and clinical significance to the biologic therapy of leukemia.
Sosman JA; Sondel PM
Bone Marrow Transplant; 1991; 7 Suppl 1():33-7. PubMed ID: 2043883
[TBL] [Abstract][Full Text] [Related]
6. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
8. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-leukemia in chronic lymphocytic leukemia.
Ben-Bassat I; Raanani P; Gale RP
Bone Marrow Transplant; 2007 Apr; 39(8):441-6. PubMed ID: 17322931
[TBL] [Abstract][Full Text] [Related]
10. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
11. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.
Weiden PL; Flournoy N; Thomas ED; Prentice R; Fefer A; Buckner CD; Storb R
N Engl J Med; 1979 May; 300(19):1068-73. PubMed ID: 34792
[TBL] [Abstract][Full Text] [Related]
12. T cell depletion in bone marrow transplantation for leukemia: current results and future directions.
Butturini A; Gale RP
Bone Marrow Transplant; 1988 May; 3(3):185-92. PubMed ID: 3048485
[TBL] [Abstract][Full Text] [Related]
13. Graft-versus-host disease after marrow transplantation.
Storb R
Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
[TBL] [Abstract][Full Text] [Related]
14. Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation.
Gowing H; Braakman E; Hagenbeek A; Lawler M; McCann SR; Pamphilon DH; Martens AC
Bone Marrow Transplant; 1998 Apr; 21(8):801-7. PubMed ID: 9603404
[TBL] [Abstract][Full Text] [Related]
15. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
[TBL] [Abstract][Full Text] [Related]
16. [Graft-versus-leukemia effect induced by abrupt discontinuation of cyclosporine A following allogeneic bone marrow transplantation].
Kanamori H; Sasaki S; Ueda S; Yamazaki E; Tamura T; Harano H; Matsuzaki M; Ogawa K; Mohri H; Okubo T
Rinsho Ketsueki; 1997 Aug; 38(8):643-6. PubMed ID: 9311269
[TBL] [Abstract][Full Text] [Related]
17. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
19. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
[TBL] [Abstract][Full Text] [Related]
20. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
